Skip to main content
Retour
MLYS logo

Mineralys Therapeutics, Inc.

Qualité des données : 100%
Survendu
MLYS
NASDAQ Healthcare Biotechnology
22,88 €
▼ 0,77 € (-3,26%)
Cap. Boursière : 1,52B
Fourchette du Jour
22,42 € 23,87 €
Fourchette 52 Semaines
10,44 € 47,65 €
Volume
784 570
Moyenne 50J / 200J
29,55 € / 29,16 €
Clôture Précédente
23,65 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -9,8 0,3
P/B 2,4 2,9
ROE % -36,9 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
46,00 € +101.0%
Low: 30,00 € High: 56,00 €
BPA Prévisionnel
-2,19 €
CA Est.
560000

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 5,23 €
2,67 € – 13,20 €
1,3 B 1
FY2029 2,48 €
1,26 € – 6,25 €
750 M 1
FY2028 -0,94 €
-1,58 € – -0,28 €
250 M 5

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -142,43M
PEG of 0,42 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-36,91%
ROIC-19,79%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio43,76
Interest Coverage0,00

Valorisation

P/E Ratio
-9,81
P/B Ratio2,35
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -154,65M
ROE -36,91% ROA -23,37%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -142,43M
ROIC -19,79% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 43,76
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -9,81 P/B Ratio 2,35
P/S Ratio N/A PEG Ratio 0,42
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,52B Enterprise Value 1,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -154,65M -177,81M -71,90M -29,80M -19,41M
EPS (Diluted) -2,29 -3,66 -1,99 -5,77 -3,89
Gross Profit -59 000,0 0,0 0,0 0,0 0,0
Operating Income -170,60M -192,40M -84,66M -31,48M -18,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 661,81M 205,90M 251,64M 114,44M 11,13M
Total Liabilities 15,11M 14,65M 10,48M 166,71M 34,05M
Shareholders' Equity 646,69M 191,26M 241,15M -52,27M -22,93M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 172,92M 114,09M 49,30M 87,70M 10,61M
Current Assets 661,39M 205,35M 249,10M 112,81M 11,12M
Current Liabilities 15,11M 14,65M 10,48M 8,07M 5,05M